Study of Rule-Based Algorithms in Anemia Management in Prevalent Hemodialysis Patients and Its Relation to Patients' Outcomes

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06996717

Enrollment

145

Registered

2025-05-30

Start date

2025-01-01

Completion date

2025-06-30

Last updated

2025-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia in End Stage Renal Disease

Brief summary

The study will assess role of rule based algorithm in anemia management in hemodialysis patients and its relation to patient's mortality

Interventions

DRUGESA

anemia management algorithm will successfully increase the number of patients in the target hemoglobin range

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients on hemodialysis for more than six months patients undergoing hemodialysis three times per week each session for 4 hours patients with urea reduction ratio\>65% patients with transferrin saturation\>20%

Exclusion criteria

* patients with terminal illness or malignancy patients receiving hemodialysis from catheter or arteriovenous graft

Design outcomes

Primary

Measure	Time frame	Description
Increase the number of patients in the target Hb range	6 months	This study will achieve better dosing of erythropoietin stimulating agents using rule based algorithms to correct anemia and avoid unnecessary extra doses of erythropoietin stimulating agents with their side effects

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026